Merck & Co. is rounding out its March deal flurry with an antibody discovery pact that could be worth as much as $838 million ...

Eli Lilly has gone big in the name of neuroscience, paying $6.3 billion in a front-loaded deal for Centessa Pharmaceuticals ...

Lipella Pharmaceuticals’ ambition to develop the first treatment for an inflammatory mouth condition has reached the end of the road, with the biotech ...

Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ ...

Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune ...

One of the world’s leading investment firms has broken its own record with the closing of its $6.3 billion Blackstone Life ...

A phase 3 trial of AstraZeneca’s rare metabolic disease prospect has missed its primary endpoint, raising doubts about the ...

After being knocked back in 2024, serial biotech acquirer Kevin Tang has used a different route to finally get his hands on Kezar Life Sciences.   | Autoimmune specialist Aurinia, which named Kevin ...

Not content with lining up one potential rival to Amgen’s Tepezza, Viridian Therapeutics has scored a phase 3 win for another thyroid eye disease (TED) prospect. But the candidate's inability to meet ...

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

Merck & Co. has lifted the lid on the third successful phase 3 trial of its PCSK9 inhibitor, showing the edge the cardiovascular disease prospect has over other oral non-statin therapies.

Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune ...